P
Pulike Biological Engineering Inc
SSE:603566
Pulike Biological Engineering Inc
SSE:603566
Price:
12.42
CNY
-1.04%
Market Closed
Market Cap:
4.3B
CNY
Balance Sheet
Balance Sheet Decomposition
Pulike Biological Engineering Inc
Pulike Biological Engineering Inc
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 508.5m |
| Receivables | 468.9m |
| Other Current Assets | 213.8m |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 353.5m |
| PP&E | 1.2B |
| Intangibles | 293.8m |
| Other Non-Current Assets | 38.3m |
Balance Sheet
Pulike Biological Engineering Inc
Pulike Biological Engineering Inc
Currency: CNY
Millions
Annual
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
214
|
391
|
429
|
250
|
438
|
283
|
240
|
165
|
282
|
312
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
165
|
282
|
312
|
|
| Cash Equivalents |
213
|
391
|
429
|
250
|
438
|
283
|
240
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
400
|
515
|
700
|
295
|
319
|
266
|
75
|
691
|
408
|
|
| Total Receivables |
122
|
112
|
118
|
115
|
150
|
169
|
215
|
310
|
507
|
490
|
|
| Accounts Receivables |
78
|
109
|
103
|
109
|
141
|
129
|
205
|
292
|
482
|
439
|
|
| Other Receivables |
44
|
3
|
15
|
7
|
9
|
40
|
10
|
18
|
25
|
51
|
|
| Inventory |
53
|
60
|
62
|
71
|
97
|
118
|
134
|
171
|
192
|
184
|
|
| Other Current Assets |
4
|
3
|
2
|
15
|
23
|
23
|
25
|
14
|
22
|
17
|
|
| Total Current Assets |
392
|
966
|
1 125
|
1 152
|
1 003
|
912
|
880
|
733
|
1 683
|
1 409
|
|
| PP&E Net |
324
|
299
|
353
|
369
|
367
|
395
|
466
|
652
|
950
|
1 175
|
|
| PP&E Gross |
324
|
299
|
353
|
369
|
367
|
395
|
466
|
652
|
950
|
1 175
|
|
| Accumulated Depreciation |
114
|
140
|
163
|
192
|
223
|
285
|
302
|
324
|
375
|
447
|
|
| Intangible Assets |
115
|
231
|
215
|
208
|
220
|
220
|
223
|
276
|
286
|
283
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
18
|
18
|
18
|
18
|
18
|
|
| Long-Term Investments |
6
|
7
|
42
|
59
|
290
|
321
|
391
|
418
|
383
|
340
|
|
| Other Long-Term Assets |
1
|
1
|
2
|
18
|
23
|
40
|
52
|
71
|
75
|
37
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
18
|
18
|
18
|
18
|
18
|
|
| Total Assets |
838
N/A
|
1 504
+80%
|
1 737
+16%
|
1 805
+4%
|
1 903
+5%
|
1 906
+0%
|
2 029
+6%
|
2 168
+7%
|
3 396
+57%
|
3 262
-4%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
31
|
21
|
28
|
29
|
43
|
39
|
45
|
49
|
123
|
110
|
|
| Accrued Liabilities |
9
|
13
|
19
|
27
|
37
|
43
|
52
|
60
|
70
|
69
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
55
|
35
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Other Current Liabilities |
86
|
108
|
177
|
151
|
158
|
132
|
193
|
237
|
307
|
294
|
|
| Total Current Liabilities |
126
|
142
|
224
|
207
|
238
|
214
|
290
|
346
|
556
|
508
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
2
|
7
|
11
|
15
|
25
|
8
|
|
| Other Liabilities |
29
|
24
|
32
|
30
|
28
|
27
|
18
|
7
|
8
|
22
|
|
| Total Liabilities |
154
N/A
|
167
+8%
|
256
+54%
|
236
-8%
|
268
+13%
|
247
-8%
|
319
+29%
|
368
+15%
|
592
+61%
|
538
-9%
|
|
| Equity | |||||||||||
| Common Stock |
120
|
160
|
324
|
324
|
324
|
322
|
322
|
321
|
353
|
353
|
|
| Retained Earnings |
511
|
604
|
744
|
794
|
865
|
888
|
1 053
|
1 139
|
1 239
|
1 188
|
|
| Additional Paid In Capital |
53
|
573
|
459
|
478
|
474
|
449
|
469
|
473
|
1 346
|
1 324
|
|
| Treasury Stock |
0
|
0
|
46
|
27
|
27
|
0
|
134
|
134
|
134
|
141
|
|
| Total Equity |
684
N/A
|
1 337
+96%
|
1 481
+11%
|
1 569
+6%
|
1 636
+4%
|
1 658
+1%
|
1 710
+3%
|
1 800
+5%
|
2 804
+56%
|
2 724
-3%
|
|
| Total Liabilities & Equity |
838
N/A
|
1 504
+80%
|
1 737
+16%
|
1 805
+4%
|
1 903
+5%
|
1 906
+0%
|
2 029
+6%
|
2 168
+7%
|
3 396
+57%
|
3 262
-4%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
240
|
320
|
320
|
324
|
324
|
322
|
322
|
315
|
346
|
346
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
